Abstract:142 Background: Early tumor shrinkage (ETS) and the depth of response (DpR) are early on-treatment surrogate markers for survival in patients with metastatic colorectal cancer (mCRC) receiving anti-epidermal growth factor receptor (EGFR) monoclonal antibody. However, the utility of ETS and DpR for BRAF V600E mutant (MT) mCRC which has a poor prognosis remains unclear. The aim of this study is to evaluate the association between ETS and DpR and clinical outcomes in BRAF V600E MT mCRC. Methods: mCRC patients who were diagnosed BRAF V600E MT and treated with 1 st line chemotherapy from June 2011 to March 2023 at single cancer institute were enrolled. We analyzed the association between ETS and DpR and clinical outcome in patients who had at least one target lesion. Subgroup analysis of clinical factors related to progression free survival (PFS) and overall survival (OS) was performed using multivariate analysis. ETS was defined as the relative change in the sum of the longest diameters of RECIST target lesions at first follow-up CT scan compared to baseline and DpR was defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir in the absence of new lesions or progression of non-target lesions compared to baseline. Results: In total, 54 patients of BRAF V600E MT mCRC had at least one target lesion. In total of StageI-IV CRC patients, the incidence of BRAF V600E MT was 6.3% (233/3705). Patients with ETS ≥ 20% and DpR ≥ 25% (median value) were 24 (44.4%) and 27 (50%) respectively. PFS was 7.5 months (95% confidence interval (CI), 5.0-9.9) and OS was 17.1 months (95% CI, 11.7-20.2). Patients with ETS ≥ 20% had longer PFS and tended to have longer OS than those with non-ETS, with a median PFS of 9.8 months vs. 4.8 months (P Log-rank = 0.048, hazard ratio (HR), 0.55; 95% CI, 0.30-1.00), and a median OS of 22.6 months vs. 11.6 months (P Log-rank = 0.18, HR, 0.67; 95% CI, 0.37-1.21). Patients with DpR ≥ 25% had also longer PFS and OS than those with non-DpR, with a median PFS of 11.0 vs. 4.3 months (P Log-rank < 0.01, HR, 0.36; 95% CI, 0.20-0.66) and a median OS of 22.6 vs. 10.1 months (P Log-rank = 0.047, HR, 0.55; 95% CI, 0.31-1.00). Median time to DpR was 3.05 months. In multivariate analysis, DpR was significantly associated with both longer PFS (HR: 0.27, 95% CI: 0.14–0.55, P < 0.01) and OS (HR: 0.52, 95% CI: 0.29–0.96, P = 0.04). Conclusions: ETS and DpR may be early surrogate markers for clinical outcome in BRAF V600E MT mCRC who were treated with 1 st line chemotherapy.

Early Tumor Shrinkage As Predictor of Outcome in Colorectal Liver Metastases Treated with Cetuximab Plus Chemotherapy

Early Tumor Shrinkage As Predictor of Outcome in Colorectal Liver Metastases Treated with Cetuximab Plus Chemotherapy

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Patients with Kras Wild-Type Unresectable Colorectal Liver-Limited Metastases: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial (clime Study)

Tumor Response and Secondary Resectability of Colorectal Liver Metastases Following Cetuximab with Chemotherapy: A Randomized, Controlled Study

Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients with KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases

On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis

Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial

114. Long term survival following a randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases

Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.

K-ras status and efficacy of cetuximab-containing regimen in the treatment of patients with metastatic colorectal cancer

Patients with RAS Wild-Type Right-Sided Unresectable Liver-Confined Mcrc Also Benefit from Cetuximab Plus Chemotherapy in First-Line Treatment

Impact Ofkrasmutation and PTEN Expression on Cetuximab-Treated Colorectal Cancer

Standard Chemotherapy with Cetuximab for Treatment of Colorectal Cancer

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies

Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.

Plasma cetuximab concentrations correlate with survival in patients with advanced KRAS wild type colorectal cancer

Impact of Primary Tumor Side on Clinical Outcomes of First-Line Cetuximab Plus FOLFOX-4 in RAS Wild-Type Metastatic Colorectal Cancer.

Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients

Impact of Primary Tumor Side (TS) on Outcomes of Once-Every-2-weeks (q2w) Cetuximab + First-Line (1L) FOLFOX or FOLFIRI in Patients with RAS Wild-Type (wt) Metastatic Colorectal Cancer (mcrc) in the Phase 2 APEC Trial.